Viral Genetics, Inc.

Viral Genetics, Inc. (Viral Genetics) is a publicly held biotechnology company, engaged in the discovery, development and commercialization of immune based therapies using its thymus nuclear protein compound for the treatment of serious diseases and autoimmune conditions. Viral Genetics is focused on developing therapies to treat HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. The lead product candidate of Viral Genetics is VGV-1, which is being studied in clinical trials for the treatment for HIV infection and AIDS. Recently, the company entered into exclusive license agreement with University of Colorado, to develop cancer therapies based on the work of Karen Newell. The company is headquartered in San Marino, California, the US.

Street: 
2290 Huntington Drive
City: 
San Marino
Postcode: 
91108
Federal State : 
United States
WebSite: 
www.viralgenetics.com
Fax: 
1-626-3345324

Company Index Score

Current Index Score Historical Index Score
  • Viral Genetics, Inc. currently scores 50 % in the index.
  • Viral Genetics, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Viral Genetics, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets